SYNGENE Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹917.1 Cr
verified against source
Revenue YoY
-3%
reported change
EBITDA
₹209 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene reported a disappointing Q3 FY26 with revenue from operations declining 3% YoY to Rs 917 crore, driven primarily by ongoing headwinds from a single large molecule product (Librela) from its largest biologics customer Zoetis. Operating EBITDA stood at Rs 209 crore with a 23% margin, significantly compressed from 30% in Q3 FY25, reflecting lower revenue, hedge losses of Rs 23.3 crore, and higher staff costs. PAT before exceptional items fell 44% YoY to Rs 73 crore. The full-year guidance was revised to a 3%-5% revenue decline with EBITDA margins of 22%-23%. Management characterized underlying business growth, excluding the single product impact, as high single-digit to low double-digit in constant currency. The BMS partnership was extended through 2035, providing a 10-year strategic horizon with over 700 scientists deployed. CapEx guidance stands at $45 million for FY26 with a net cash balance of Rs 902 crore. The single-product impact is expected to continue beyond Q4 and into FY27 before fully playing out. Key risks include customer concentration, capacity underutilization at newer facilities, and management's inability to provide specific timelines or compensation sources for the Zoetis product shortfall.
Colored figures show movement against the previous available record.
Guidance to track
- The company revised its full-year guidance downward from mid-single-digit growth to a 3%-5% revenue decline, driven by the ongoing impact from the single large molecule product from its largest biologics customer. The guidance is in constant currency terms.
- Full-year operating EBITDA margin is expected in the range of 22%-23%, a significant compression from 27% in FY25, reflecting lower revenue, higher operating costs from new facilities, and the hedge loss impact.
- The company continues to invest in building capabilities and technologies across research services and CDMO, including DMPK Biology, ADC Labs, oral solid dosage capabilities, and Stelis facility integration.
- The normalized effective tax rate for the quarter was 22.8% compared to 22.2% in the same quarter last year, with full-year ETR expected in the 21%-23% range.
Risks flagged
- The single commercial-stage biologics product (Librela) from the largest customer Zoetis is causing substantial revenue headwinds. Management expects this impact to continue beyond Q4 and into FY27. The magnitude and duration remain uncertain as the customer deals with both inventory corrections and product-specific issues.
- Both the Mangalore small molecules facility and the Stelis US biologics facility are experiencing lower than expected capacity utilization. Management acknowledged that performance at Mangalore has not met expectations, though early signs of improvement are emerging. The Stelis facility has just completed validation and is hiring, with no immediate large customer commitments disclosed.
- Management declined to provide specific guidance on when the single-product impact will normalize or what other programs/products could offset the shortfall. Analyst questions on the timeline for recovery and potential new products from Zoetis (Librela successor) were answered with 'we'll update at full-year' or vague commitments about ongoing dialogue.
- Other direct costs (primarily power and utilities) increased 2% YoY in Q3 due to new facilities at Stelis in the US and the biologics facility in Bangalore. Other expenses rose 5% YoY due to automation and digital initiatives. Staff costs increased 8% YoY. These cost increases are occurring while revenue is declining, compressing margins.
Key quotes
- The key variable impacting our Q3 performance has been the ongoing impact related to a single commercial stage product from our largest large molecule biologics customer.
- We expect the impact of this single product to play out in the coming quarters. It will go beyond Q4.
- If I was to exclude the one-off product, the rest of the business is growing in high single digits, low double digits in constant currency terms.
- We are looking to build a wide and diversified business across the platforms and build more large relationships so that exposure to these types of single product events would be minimized.
Research modules